Authors: Tatokoro, Manabu
Koga, Fumitaka
Yoshida, Soichiro
Kihara, Kazunori
Title: Heat shock protein 90 targeting therapy
Other Titles: state of the art and future perspective
Language (ISO): en
Abstract: Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that plays a role in stabilizing and activating more than 200 client proteins. It is required for the stability and function of numerous oncogenic signaling proteins that determine the hallmarks of cancer. Since the initial discovery of the first Hsp90 inhibitor in the 1970s, multiple phase II and III clinical trials of several Hsp90 inhibitors have been undertaken. This review provides an overview of the current status on clinical trials of Hsp90 inhibitors and future perspectives on novel anticancer strategies using Hsp90 inhibitors.
Subject Headings: Hsp90 inhibitor
cancer
clinical trial
bladder cancer
URI: http://hdl.handle.net/2003/34053
http://dx.doi.org/10.17877/DE290R-7601
Issue Date: 2015-01-06
Appears in Collections:Review Articles

Files in This Item:
File Description SizeFormat 
Koga_06012015_proof.pdfDNB119.52 kBAdobe PDFView/Open


This item is protected by original copyright



All resources in the repository are protected by copyright.